Integrative Mapping of Pre-existing Immune Landscapes for Vaccine Response Prediction
Guardat en:
| Publicat a: | bioRxiv (Jan 23, 2025) |
|---|---|
| Autor principal: | |
| Altres autors: | , , , , , , , , , , , , , , , |
| Publicat: |
Cold Spring Harbor Laboratory Press
|
| Matèries: | |
| Accés en línia: | Citation/Abstract Full text outside of ProQuest |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3158976036 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2692-8205 | ||
| 024 | 7 | |a 10.1101/2025.01.22.634302 |2 doi | |
| 035 | |a 3158976036 | ||
| 045 | 0 | |b d20250123 | |
| 100 | 1 | |a Hao, Stephanie | |
| 245 | 1 | |a Integrative Mapping of Pre-existing Immune Landscapes for Vaccine Response Prediction | |
| 260 | |b Cold Spring Harbor Laboratory Press |c Jan 23, 2025 | ||
| 513 | |a Working Paper | ||
| 520 | 3 | |a Predicting individual vaccine responses remains a significant challenge due to the complexity and variability of immune processes. To address this gap, we developed immunaut, an open-source, data-driven framework implemented as an R package specifically designed for all systems vaccinologists seeking to analyze and predict immunological outcomes across diverse vaccination settings. Leveraging one of the most comprehensive live attenuated influenza vaccine (LAIV) datasets to date - 244 Gambian children enrolled in a phase 4 immunogenicity study - immunaut integrates humoral, mucosal, cellular, transcriptomic, and microbiological parameters collected before and after vaccination, providing an unprecedentedly holistic view of LAIV-induced immunity. Through advanced dimensionality reduction, clustering, and predictive modeling, immunaut identifies distinct immunophenotypic responder profiles and their underlying baseline determinants. In this study, immunaut delineated three immunophenotypes: (1) CD8 T-cell responders, marked by strong baseline mucosal immunity and extensive prior influenza virus exposure that boosts memory CD8 T-cell responses, without generating influenza virus-specific antibody responses; (2) Mucosal responders, characterized by pre-existing systemic influenza A virus immunity (specifically to H3N2) and stable epithelial integrity, leading to potent mucosal IgA expansions and subsequent seroconversion to influenza B virus; and (3) Systemic, broad influenza A virus responders, who start with relatively naive immunity and leverage greater initial viral replication to drive broad systemic antibody responses against multiple influenza A virus variants beyond those included in the LAIV vaccine. By integrating pathway-level analysis, model-derived contribution scores, and hierarchical decision rules, immunaut elucidates how distinct immunological landscapes shape each response trajectory and how key baseline features, including pre-existing immunity, mucosal preparedness, and cellular support, dictate vaccine outcomes. Collectively, these findings emphasize the power of integrative, predictive frameworks to advance precision vaccinology, and highlight immunaut as a versatile, community-available resource for optimizing immunization strategies across diverse populations and vaccine platforms.Competing Interest StatementAuthors declare that they have no competing interests. Florian Krammer (FK) declares the following conflicts of interest. The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines on which FK is listed as inventor. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines, and influenza virus therapeutics, which list FK as co-inventor, and FK has received royalty payments from some of these patents. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. FK is a co-founder and scientific advisory board member of Castlevax. FK has consulted for Merck, GSK, Sanofi, Curevac, Seqirus, and Pfizer and is currently consulting for 3rd Rock Ventures, Gritstone, and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics.Footnotes* https://zenodo.org/records/14719593* https://github.com/atomiclaboratory/immunaut* https://cran.r-project.org/web/packages/immunaut/index.html | |
| 610 | 4 | |a Icahn School of Medicine at Mount Sinai | |
| 653 | |a Vaccines | ||
| 653 | |a Serological tests | ||
| 653 | |a Patent applications | ||
| 653 | |a Severe acute respiratory syndrome coronavirus 2 | ||
| 653 | |a Lymphocytes T | ||
| 653 | |a Immunology | ||
| 653 | |a Influenza | ||
| 653 | |a Patents | ||
| 653 | |a Transcriptomics | ||
| 653 | |a Immune system | ||
| 653 | |a Drug development | ||
| 653 | |a Serology | ||
| 653 | |a Immunological memory | ||
| 653 | |a Influenza B | ||
| 653 | |a Influenza A | ||
| 653 | |a Vaccine development | ||
| 653 | |a Inventors | ||
| 653 | |a Mucosal immunity | ||
| 653 | |a Immunogenicity | ||
| 653 | |a Viruses | ||
| 653 | |a CD8 antigen | ||
| 653 | |a Seroconversion | ||
| 653 | |a Immunoglobulin A | ||
| 700 | 1 | |a Tomic, Ivan | |
| 700 | 1 | |a Lindsey, Benjamin B | |
| 700 | 1 | |a Jagne, Ya Jankey | |
| 700 | 1 | |a Hoschler, Katja | |
| 700 | 1 | |a Meijer, Adam | |
| 700 | 1 | |a Carreno Quiroz, Juan Manuel | |
| 700 | 1 | |a Meade, Philip | |
| 700 | 1 | |a Sano, Kaori | |
| 700 | 1 | |a Peno, Chikondi | |
| 700 | 1 | |a Costa Martins, Andre G | |
| 700 | 1 | |a Bogaert, Debby | |
| 700 | 1 | |a Kampmann, Beate | |
| 700 | 1 | |a Nakaya, Helder | |
| 700 | 1 | |a Krammer, Florian | |
| 700 | 1 | |a De Silva, Thushan I | |
| 700 | 1 | |a Tomic, Adriana | |
| 773 | 0 | |t bioRxiv |g (Jan 23, 2025) | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3158976036/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full text outside of ProQuest |u https://www.biorxiv.org/content/10.1101/2025.01.22.634302v1 |